Literature DB >> 14985467

Cyclin-dependent kinase 6 inhibits proliferation of human mammary epithelial cells.

Joseph J Lucas1, Joanne Domenico, Erwin W Gelfand.   

Abstract

Many defects in cancer cells are in molecules regulating G(1)-phase cyclin-dependent kinases (cdks), which are responsible for modulating the activities of Rb family growth-suppressing proteins. Models for understanding how such defects affect proliferation assume that cdks are responsible for sequentially phosphorylating, and hence inactivating, the growth-suppressing functions of Rb family proteins, thus promoting cell cycle progression. However, cdks also play a role in formation of growth-suppressing forms of pRb family molecules, including the "hypophosphorylated" species of pRb itself. Here, it is shown that normal human mammary epithelial cells have a high amount of cdk6 protein and activity, but all breast tumor-derived cell lines analyzed had reduced levels, with several having little or no cdk6. Immunohistochemical studies showed reduced levels of cdk6 in breast tumor cells as compared with normal breast tissue in vivo. Cdk6 levels in two breast tumor cell lines were restored to those characteristic of normal human mammary epithelial cells by DNA transfection. The cells had a reduced growth rate compared with parental tumor cells; cells that lost ectopic expression of cdk6 reverted to the faster growth rate of parental cells. Cell lines with restored cdk6 levels accumulated higher amounts of the Rb family protein p130 as well as E2F4, a suppressing member of the E2F family of transcription factors, in their nuclei. The results suggest that cdk6 restrains rather than stimulates breast epithelial cell proliferation and that its loss or down-regulation could play a role in breast tumor development.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14985467

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  18 in total

1.  Epigenetic inactivation of the potential tumor suppressor gene FOXF1 in breast cancer.

Authors:  Pang-Kuo Lo; Ji Shin Lee; Xiaohui Liang; Liangfeng Han; Tsuyoshi Mori; Mary Jo Fackler; Helen Sadik; Pedram Argani; Tej K Pandita; Saraswati Sukumar
Journal:  Cancer Res       Date:  2010-06-29       Impact factor: 12.701

2.  IFITM3 knockdown reduces the expression of CCND1 and CDK4 and suppresses the growth of oral squamous cell carcinoma cells.

Authors:  Chai Phei Gan; Kin Kit Sam; Pei San Yee; Nur Syafinaz Zainal; Bernard Kok Bang Lee; Zainal Ariff Abdul Rahman; Vyomesh Patel; Aik Choon Tan; Rosnah Binti Zain; Sok Ching Cheong
Journal:  Cell Oncol (Dordr)       Date:  2019-04-04       Impact factor: 6.730

3.  Proteotranscriptomic Measurements of E6-Associated Protein (E6AP) Targets in DU145 Prostate Cancer Cells.

Authors:  Twishi Gulati; Cheng Huang; Franco Caramia; Dinesh Raghu; Piotr J Paul; Robert J A Goode; Simon P Keam; Scott G Williams; Sue Haupt; Oded Kleifeld; Ralf B Schittenhelm; Cristina Gamell; Ygal Haupt
Journal:  Mol Cell Proteomics       Date:  2018-02-20       Impact factor: 5.911

Review 4.  The other side of the coin: the tumor-suppressive aspect of oncogenes and the oncogenic aspect of tumor-suppressive genes, such as those along the CCND-CDK4/6-RB axis.

Authors:  Xiaomin Lou; Ju Zhang; Siqi Liu; Ningzhi Xu; D Joshua Liao
Journal:  Cell Cycle       Date:  2014-05-05       Impact factor: 4.534

5.  Early G₁ cyclin-dependent kinases as prognostic markers and potential therapeutic targets in esophageal adenocarcinoma.

Authors:  Amin Ismail; Santhoshi Bandla; Marie Reveiller; Liana Toia; Zhongren Zhou; William E Gooding; Irina Kalatskaya; Lincoln Stein; Mary D'Souza; Virginia R Litle; Jeffrey H Peters; Arjun Pennathur; James D Luketich; Tony E Godfrey
Journal:  Clin Cancer Res       Date:  2011-05-18       Impact factor: 12.531

6.  Parkin enhances the expression of cyclin-dependent kinase 6 and negatively regulates the proliferation of breast cancer cells.

Authors:  Shiam-Peng Tay; Calvin W S Yeo; Chou Chai; Pei-Jou Chua; Hui-Mei Tan; Alex X Y Ang; Daniel L H Yip; Jian-Xiong Sung; Puay Hoon Tan; Boon-Huat Bay; Siew-Heng Wong; Carol Tang; Jeanne M M Tan; Kah-Leong Lim
Journal:  J Biol Chem       Date:  2010-07-14       Impact factor: 5.157

7.  Anti-cell growth and anti-cancer stem cell activity of the CDK4/6 inhibitor palbociclib in breast cancer cells.

Authors:  Emi Kishino; Ryohei Ogata; Wataru Saitoh; Yoshikazu Koike; Yusuke Ohta; Naoki Kanomata; Junichi Kurebayashi
Journal:  Breast Cancer       Date:  2019-12-10       Impact factor: 4.239

8.  Selective anticancer activity of a hexapeptide with sequence homology to a non-kinase domain of Cyclin Dependent Kinase 4.

Authors:  Hilmar M Warenius; Jeremy D Kilburn; Jon W Essex; Richard I Maurer; Jeremy P Blaydes; Usha Agarwala; Laurence A Seabra
Journal:  Mol Cancer       Date:  2011-06-13       Impact factor: 27.401

9.  Data perturbation independent diagnosis and validation of breast cancer subtypes using clustering and patterns.

Authors:  G Alexe; G S Dalgin; R Ramaswamy; C Delisi; G Bhanot
Journal:  Cancer Inform       Date:  2007-02-19

10.  A list of candidate cancer biomarkers for targeted proteomics.

Authors:  Malu Polanski; N Leigh Anderson
Journal:  Biomark Insights       Date:  2007-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.